A stock market site by Business Insider with real-time data, custom charts and breaking news. Get the latest on stocks, commodities, currencies, funds, rates, ETFs, and more.

  • 31,386articles · 365d
  • 4+ hour agolatest article
  • Sep 14, 2025earliest in window
  • 93%with images
  • 290avg words
articles per day
Categories
  • Economy, Business & Finance 26,602
  • Finance & Business 22,238
  • News 10,076
  • Finance 4,949
  • Business & Industrial 4,919
  • Health & Wellness 3,722
  • Medical 2,567
  • Computers & Electronics 1,147

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

markets.businessinsider.com
markets.businessinsider.com > news > stocks > tonix-pharmaceuticals-announces-u-s-commercial-availability-of-tonmya-cyclobenzaprine-hcl-sublingual-tablets-as-a-first-in-class-fibromyalgia-treatment-1035568876

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

9+ mon, 3+ week ago   (284+ words) TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years “For years, fibromyalgia patients have struggled with limited treatment options that often fall short. The availability…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > tonix-pharmaceuticals-presented-data-on-tonmya-cyclobenzaprine-hcl-sublingual-tablets-at-the-2025-american-college-of-rheumatology-acr-convergence-1035431989

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

10+ mon, 2+ week ago   (335+ words) Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence Tonmya demonstrated significant reduction…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > kymera-therapeutics-presents-new-preclinical-data-for-kt-579-a-first-in-class-oral-irf5-degrader-at-the-american-college-of-rheumatology-annual-meeting-1035431978

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

10+ mon, 2+ week ago   (160+ words) KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1 testing expected to begin in early 2026 Collectively,…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > spyre-therapeutics-announces-poster-presentations-at-american-college-of-rheumatology-acr-convergence-2025-1035423913

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

10+ mon, 2+ week ago   (169+ words) WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting-1035413113

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

10+ mon, 3+ week ago   (310+ words) In addition to the poster presentation, Nkarta will exhibit at booth #1801, where attendees can meet with Nkarta representatives to discuss the company’s clinical programs. Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting SOUTH SAN FRANCISCO,…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > tonix-pharmaceuticals-announces-first-patient-dosed-in-the-investigator-initiated-focus-study-of-tonix-s-intranasal-potentiated-oxytocin-in-avp-d-conducted-by-massachusetts-general-hospital-1035412209

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

10+ mon, 3+ week ago   (471+ words) 1Meyerowitz JG, et al. Nat Struct Mol Biol. 2022. 29(3):274-281. 2Bharadwaj VN, et al. Pharmaceutics. 2022 14(5):1105.3Bharadwaj VN, et al. Pharmaceutics. 2021. Jul 16;13(7):1088.4Yeomans, DC et al. 2017. US patent US20173680955Shafer SL, et al. Br J Anaesth. 2025. 134(5):1513-1522. Investigator-Initiated Studies Using TNX-1900 at Mass General Hospital (MGH) In addition to the…...